Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
LATEST POSTS
- 1
Judge sets $60K bond for Florida congresswoman accused of stealing $5M in COVID-19 funds - 2Which European countries have mandatory or voluntary military service
- 3Lockheed Martin opens new hypersonic weapons facility
- 4Hypothermia claims newborn in Gaza and more babies are at risk, doctor says
- 5Nutrient Rich Organic products: Lift Your Wellbeing
- Instructions to Safeguard Your Speculations In the midst of Changing Disc Rates
- SpaceX launches Italian Earth-observing satellite to orbit on the 1st mission of 2026 (video)
- The Eastern Bongo, Kenya’s Rare Forest Antelope on the Brink
- NASA astronauts to return from space early due to an 'unexpected medical issue.' What happened — and when are they coming home?
- 6 Web-based Course Stages for Successful Learning and Educating
- Sports Shoes of 2024: Upgrade Execution and Solace
- US bishops officially ban gender-affirming care at Catholic hospitals
- Why haven’t humans been back to the moon in over 50 years?
- CDC pauses dozens of types of lab testing during evaluation and in wake of downsizing
